Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
1
Issued Date
2022-06-01
Resource Type
eISSN
2076393X
Scopus ID
2-s2.0-85131551698
Journal Title
Vaccines
Volume
10
Issue
6
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccines Vol.10 No.6 (2022)
Suggested Citation
Chantasrisawad N., Puthanakit T., Tangsathapornpong A., Techasaensiri C., Phongsamart W., Suwanpakdee D., Jaruampornpan P., Sophonphan J., Suntarattiwong P., Chotpitayasunondh T. Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases. Vaccines Vol.10 No.6 (2022). doi:10.3390/vaccines10060871 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/84980
Title
Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
Author's Affiliation
Siriraj Hospital
King Chulalongkorn Memorial Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Thammasat University
Thailand National Center for Genetic Engineering and Biotechnology
Queen Sirikit National Institute of Child Health
Phramongkutklao College of Medicine
Faculty of Medicine, Chulalongkorn University
King Chulalongkorn Memorial Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Thammasat University
Thailand National Center for Genetic Engineering and Biotechnology
Queen Sirikit National Institute of Child Health
Phramongkutklao College of Medicine
Faculty of Medicine, Chulalongkorn University
Other Contributor(s)
Abstract
Adolescents with underlying diseases are at risk of severe COVID-19. The immune response of BNT162b2 may be poor among immunocompromised adolescents. We aim to describe immuno-genicity of mRNA BNT162b2 among adolescents who are immunocompromised or have chronic dis-eases. We recruited adolescents 12–18 years of age; group A impaired-immunity (post-transplantation, cancer, on immunosuppressive drugs) and group B chronic diseases. A two-dose regimen of BNT162b2 was given. Immunogenicity was determined by surrogate virus neutralization test (sVNT) and IgG against receptor-binding domain (RBD). From August to October 2021, 312 adolescents, with a median age (IQR) of 15 years (13.7–16.5), were enrolled (group A 100, group B 212). The geometric means (GMs) of sVNT (%inhibition) against Delta strain and anti-RBD IgG (BAU/mL) after the 2nd dose among group A were: post-transplantation recipients 52.9 (95% CI 37.7–74.2) and 233.6 (95% CI 79–690.6); adolescents with cancer 62.3 (95% CI 29.2–133.1) and 214.9(95% CI 34.2–1348.6); and adolescents with other immunosuppressive conditions 66.7 (95% CI 52.4–84.8) and 849.8 (95% CI 393.4– 1835.8). In group B were: adolescents living with HIV 98 (95% CI 97.3–98.8) and 3240.3 (95% CI 2699– 3890.2), and adolescents with other chronic disease 98.6 (95% CI 98.3–98.9) and 3818.5 (95% CI 3490.4– 4177.4). At day 90, immunity declined; among impaired-immunity participants were 43.9 (95% CI 30.8–62.4) and 178.7 (95% CI 91.2–350.1) and adolescents with chronic diseases were 90.6 (95% CI 88.4– 92.8) and 1037.1 (95% CI 933.3–1152.5). In conclusion, adolescents with impaired immunity had a poor response to 2-doses of BNT162b2, additional dose should be considered. Adolescents with chronic diseases had excellent response but immunity waned after 3 m, booster dose may be required.